Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Accounts Payables: 2013-2024

Historic Accounts Payables for Ocular Therapeutix (OCUL) over the last 12 years, with Dec 2024 value amounting to $4.2 million.

  • Ocular Therapeutix's Accounts Payables rose 56.46% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 56.46%. This contributed to the annual value of $4.2 million for FY2024, which is 4.85% down from last year.
  • Per Ocular Therapeutix's latest filing, its Accounts Payables stood at $4.2 million for FY2024, which was down 4.85% from $4.4 million recorded in FY2023.
  • Over the past 5 years, Ocular Therapeutix's Accounts Payables peaked at $5.1 million during FY2022, and registered a low of $2.7 million during FY2020.
  • Moreover, its 3-year median value for Accounts Payables was $4.4 million (2023), whereas its average is $4.6 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first declined by 17.11% in 2020, then soared by 69.51% in 2021.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Accounts Payables stood at $2.7 million in 2020, then surged by 69.51% to $4.6 million in 2021, then grew by 11.56% to $5.1 million in 2022, then dropped by 14.33% to $4.4 million in 2023, then fell by 4.85% to $4.2 million in 2024.